Since there is significantly higher TRPV1 expression in patients with GIM or CAG compared with controls, the question arises whether this is due to a tumor-promoting effect eventually resulting in GC or a counterbalancing tumor-suppressant mechanism directed at mitigating the pro-cancerous processes. Here, TRPV1 is linked to neoplasm.